Ipca Laboratories Ltd
IPCALAB
Company Profile
Business description
Ipca Laboratories Ltd is a pharmaceutical company. The company's principal activity is the Development, Manufacturing, and Marketing of Pharmaceuticals Products. The company's API products include Atenolol (anti-hypertensive), Chloroquine Phosphate (anti-malarial), Chlorthalidone (diuretic), Furosemide (diuretic), Hydroxychloroquine Sulphate (DMARD), Losartan. The company has only one reportable primary business segment, pharmaceuticals.
Contact
125, Kandivli Industrial Estate
Kandivli (West)
MumbaiMH400067
INDT: +91 2262105000
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - Specialty & Generic
Fiscal Year End
31 March 2025
Employees
22,841
Stocks News & Analysis
stocks
Are investors missing the boat on this future ASX leader?
The market is underestimating the clear path to profitability.
stocks
ASX shares plunge but remain undervalued
Shares drop 17% after guidance is revised but we still see value.
stocks
Ask the analyst: Why have markets shunned APA Group?
Australia's premier gas infrastructure firm used to be a market darling, but its shares have taken a severe de-rating in recent years.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,471.80 | 39.90 | 0.47% |
| CAC 40 | 7,423.67 | 15.03 | 0.20% |
| DAX 40 | 20,271.33 | 138.48 | 0.69% |
| Dow JONES (US) | 42,518.28 | 221.16 | 0.52% |
| FTSE 100 | 8,201.54 | 22.65 | -0.28% |
| HKSE | 19,219.78 | 345.64 | 1.83% |
| NASDAQ | 19,044.39 | 43.71 | -0.23% |
| Nikkei 225 | 38,474.30 | 716.10 | -1.83% |
| NZX 50 Index | 12,879.60 | 4.78 | -0.04% |
| S&P 500 | 5,842.91 | 6.69 | 0.11% |
| S&P/ASX 200 | 8,231.00 | 39.10 | 0.48% |
| SSE Composite Index | 3,240.94 | 80.19 | 2.54% |